Loading...

World-Class Retina Care. Community-Based Caring.

Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial

Posted On June 7, 2023 / By / Posted in Blog

Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial

On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related

read more
Posted On February 21, 2023 / By / Posted in Blog

FDA Approves First Treatment for Geographic Atrophy

On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina

read more
Posted On November 30, 2021 / By / Posted in Blog

What is Geographic Atrophy?

Approximately 20% of patients with age-related macular degeneration (AMD) will develop a condition called geographic atrophy (GA). It is considered a late stage of AMD and involves chronic, progressive degeneration of regions

read more
Posted On October 19, 2021 / By / Posted in Blog

Dr. Abbey to Speak at Upcoming Retina World Congress Medical Education Event

On October 24, 2021, Texas Retina Associates’ Ashkan M. Abbey, MD, will serve on a distinguished panel of presenters from across the country for a Retina World Congress continuing medical education (CME)

read more